Deciphex is a Dublin-based technology company specializing in AI-powered digital pathology platforms that enhance diagnostic efficiency for healthcare providers and pharmaceutical firms. Founded in 2017, it offers three core brands—Diagnexia, Patholytix, and Diagnexia Analytix—that connect global networks of subspecialty pathologists with AI-driven workflows, digital imaging, and analytics to accelerate diagnoses, streamline drug development, and improve patient outcomes.[1][2][3] These solutions serve hospitals (e.g., reducing NHS wait times from 2 months to 2 days), top pharma companies (speeding preclinical testing), and life sciences organizations facing pathology shortages, with recent €31M ($32.3M) Series C funding in January 2025 fueling global expansion.[3][4]
Deciphex was founded in 2017 in Dublin, Ireland, by CEO Donal O'Shea, a serial entrepreneur with a Ph.D. in Computer Vision from Dublin City University and over 20 years in life sciences, diagnostics, and technology, including prior startup exits via trade sales.[1][2] The idea emerged from recognizing the pathology productivity gap—limited resources, long wait times, and inefficient workflows—and transitioned traditional methods to AI by optimizing image capture, global pathologist networks, and AI analysis for clinical trials and diagnostics.[2][3] Early traction built through platforms like Diagnexia for rapid diagnostics and Patholytix for GLP-compliant research, culminating in partnerships with 9/10 top pharma companies and NHS integration; pivotal growth included the 2025 Series C round led by Molten Ventures and key hires like CFO Greg Wigmore.[3][4]
Deciphex stands out in digital pathology through integrated AI and human expertise:
Deciphex rides the AI-digital pathology wave, addressing global shortages amid rising cancer rates and diagnostic demands, where traditional microscopy lags.[1][3] Timing aligns with healthcare digitization post-COVID, regulatory shifts favoring AI (e.g., GLP compliance), and pharma's push for faster trials amid $2T+ annual R&D spends.[2][3] Market forces like NHS 28-day diagnosis targets and underserved regions amplify its impact, democratizing expertise while competitors like Paige and Ibex focus narrower on cancer AI.[1] It influences the ecosystem by pioneering data repositories for foundation models, enabling broader AI adoption in pathology and bridging clinical-research gaps for improved drug safety and equity.[3]
Deciphex is primed for hypergrowth, leveraging its €31M raise to expand AI models, global networks, and pharma partnerships amid a pathology crisis projected to worsen.[4] Trends like multimodal AI, real-world evidence mandates, and telepathology will shape its path, potentially capturing share from fragmented markets. Its influence may evolve into an industry standard-setter, powering next-gen diagnostics and trials—transforming "productivity gap" into abundance, much like how it already cut NHS waits from months to days.[3]
Deciphex has raised $57.0M in total across 5 funding rounds.
Deciphex's investors include Act Venture Capital, Amino Collective, Hummingbird Ventures, MizMaa Ventures, Molten Ventures, Not Boring Capital, Seroba Life Sciences.
Deciphex has raised $57.0M across 5 funding rounds. Most recently, it raised $32.0M Series C in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $32.0M Series C | Act Venture Capital, Amino Collective, Hummingbird Ventures, MizMaa Ventures, Molten Ventures, Not Boring Capital, Seroba Life Sciences | |
| Jan 1, 2023 | $4.0M Series B | Act Venture Capital, Molten Ventures, Seroba Life Sciences | |
| May 1, 2022 | $12.0M Series B | Act Venture Capital, Molten Ventures, Seroba Life Sciences | |
| Jul 1, 2020 | $6.0M Series A | Act Venture Capital, Molten Ventures, Seroba Life Sciences | |
| Apr 1, 2019 | $3.0M Venture Round | Act Venture Capital, Molten Ventures, Seroba Life Sciences |
